{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:05:23Z","timestamp":1785150323571,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute on Drug Abuse, National Institute s of Health, USA","award":["DA034806"],"award-info":[{"award-number":["DA034806"]}]},{"name":"National Institute on Drug Abuse, National Institute s of Health, USA","award":["DA033426"],"award-info":[{"award-number":["DA033426"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373390"],"award-info":[{"award-number":["81373390"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.pharmthera.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:02:40Z","timestamp":1489708960000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Imidazoline I 2 receptors: An update"],"prefix":"10.1016","volume":"178","author":[{"given":"Jun-Xu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.03.009_bb0005","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.6b00426","article-title":"Neuroprotective effects of a structurally new family of high affinity imidazoline I2 receptor ligands","author":"Abas","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.03.009_bb0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1476-5381.2011.01649_1.x","article-title":"Guide to Receptors and Channels (GRAC), 5th edition","volume":"164","author":"Alexander","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.03.009_bb0015","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/j.1471-4159.2006.03662.x","article-title":"Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice","volume":"96","author":"Anderson","year":"2006","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/(SICI)1097-4547(19991201)58:5<690::AID-JNR10>3.0.CO;2-L","article-title":"Idazoxan does not prevent but worsens focal hypoxic-ischemic brain damage in neonatal Wistar rats","volume":"58","author":"Antier","year":"1999","journal-title":"Journal of Neuroscience Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.03.009_bb0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.nurt.2009.07.009","article-title":"Preclinical and early clinical investigations related to monoaminergic pain modulation","volume":"6","author":"Bannister","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/SPC.0000000000000207","article-title":"What do monoamines do in pain modulation?","volume":"10","author":"Bannister","year":"2016","journal-title":"Current Opinion in Supportive and Palliative Care"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0035","doi-asserted-by":"crossref","DOI":"10.3410\/M1-83","article-title":"The importance of the descending monoamine system for the pain experience and its treatment","volume":"1","author":"Bee","year":"2009","journal-title":"F1000 Medicine Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjp.0702031","article-title":"Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands","volume":"125","author":"Boronat","year":"1998","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0045","series-title":"Goodman and Gilman's the pharmacological basis of Therapeutics","author":"Brunton","year":"2011"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.03.009_bb0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0006-291X(87)80177-8","article-title":"Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney","volume":"147","author":"Coupry","year":"1987","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1440-1681.1997.tb01808.x","article-title":"Effects of alpha 2-adrenoceptor antagonists and imidazoline2-receptor ligands on neuronal damage in global ischaemia in the rat","volume":"24","author":"Craven","year":"1997","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1476-5381.1992.tb14300.x","article-title":"Imidazoline binding sites in human placenta: Evidence for heterogeneity and a search for physiological function","volume":"106","author":"Diamant","year":"1992","journal-title":"British Journal of Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.03.009_bb0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","article-title":"'Seeing through a glass darkly': Casting light on imidazoline 'I' sites","volume":"19","author":"Eglen","year":"1998","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(87)90125-7","article-title":"Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla","volume":"134","author":"Ernsberger","year":"1987","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0075","first-page":"111","article-title":"Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain","volume":"4","author":"Ferrari","year":"2011","journal-title":"Journal of Pain Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269881112450785","article-title":"Chronic treatment with selective I2-imidazoline receptor ligands decreases the content of pro-apoptotic markers in rat brain","volume":"27","author":"Garau","year":"2013","journal-title":"Journal of Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2006.09.031","article-title":"Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects","volume":"553","author":"Gentili","year":"2006","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/jcbfm.1989.25","article-title":"Postischemic administration of idazoxan, an alpha-2 adrenergic receptor antagonist, decreases neuronal damage in the rat brain","volume":"9","author":"Gustafson","year":"1989","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.03.009_bb0095","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/jcbfm.1990.145","article-title":"Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: Influence of time of administration and possible mechanisms of action","volume":"10","author":"Gustafson","year":"1990","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.03.009_bb0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.bbrc.2012.06.152","article-title":"Neurovascular protection conferred by 2-BFI treatment during rat cerebral ischemia","volume":"424","author":"Han","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.03.009_bb0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1179\/174313209X444116","article-title":"Attenuation of ischemia-induced rat brain injury by 2-(-2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I(2) receptors","volume":"31","author":"Han","year":"2009","journal-title":"Neurological Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064894","article-title":"Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers neuroprotection","volume":"8","author":"Han","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2010.09.029","article-title":"2-(-2-benzofuranyl)-2-imidazoline induces Bcl-2 expression and provides neuroprotection against transient cerebral ischemia in rats","volume":"1361","author":"Han","year":"2010","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152506775268758","article-title":"Imidazoline receptors, novel agents and therapeutic potential","volume":"4","author":"Head","year":"2006","journal-title":"Cardiovascular & Hematological Agents in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1999.tb09344.x","article-title":"Novel selective compounds for the investigation of imidazoline receptors","volume":"881","author":"Hudson","year":"1999","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3959(87)90088-1","article-title":"The formalin test in mice: Dissociation between inflammatory and non-inflammatory pain","volume":"30","author":"Hunskaar","year":"1987","journal-title":"Pain"},{"issue":"6312","key":"10.1016\/j.pharmthera.2017.03.009_bb0135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.aaf8924","article-title":"Pain regulation by non-neuronal cells and inflammation","volume":"354","author":"Ji","year":"2016","journal-title":"Science"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2009.11.063","article-title":"Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline I(2) receptor antagonists","volume":"629","author":"Jiang","year":"2010","journal-title":"European Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.03.009_bb0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/026988119601000403","article-title":"Discriminative stimulus produced by the imidazoline I2 site ligand, 2-BFI","volume":"10","author":"Jordan","year":"1996","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.03.009_bb0150","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1177\/0269881115586936","article-title":"Immunodetection and subcellular distribution of imidazoline receptor proteins with three antibodies in mouse and human brains: Effects of treatments with I1- and I2-imidazoline drugs","volume":"29","author":"Keller","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.03.009_bb0155","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0269881116652579","article-title":"Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice","volume":"30","author":"Keller","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2009.04.044","article-title":"Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site","volume":"1279","author":"Kimura","year":"2009","journal-title":"Brain Research"},{"issue":"15","key":"10.1016\/j.pharmthera.2017.03.009_bb0165","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1111\/bph.12728","article-title":"Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats","volume":"171","author":"Lanza","year":"2014","journal-title":"British Journal of Pharmacology"},{"issue":"5149","key":"10.1016\/j.pharmthera.2017.03.009_bb0170","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.7906055","article-title":"Agmatine: An endogenous clonidine-displacing substance in the brain","volume":"263","author":"Li","year":"1994","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.03.009_bb0175","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.12555","article-title":"Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain","volume":"171","author":"Li","year":"2014","journal-title":"British Journal of Pharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","article-title":"Imidazoline I2 receptors: Target for new analgesics?","volume":"658","author":"Li","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2011.07.041","article-title":"Morphine-induced antinociception in the rat: Supra-additive interactions with imidazoline I(2) receptor ligands","volume":"669","author":"Li","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0190","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.bjp.0704579","article-title":"Characterization of the discriminable stimulus produced by 2-BFI: Effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine","volume":"135","author":"MacInnes","year":"2002","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0091-3057(03)00136-9","article-title":"Potential serotonergic and noradrenergic involvement in the discriminative stimulus effects of the selective imidazoline I2-site ligand 2-BFI","volume":"75","author":"MacInnes","year":"2003","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0200","first-page":"151","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats","volume":"5","author":"Meregalli","year":"2012","journal-title":"Journal of Pain Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.03.009_bb0205","first-page":"369","article-title":"Keeping an eye on the I site: Imidazoline-preferring receptors","volume":"13","author":"Michel","year":"1992","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejphar.2013.09.016","article-title":"Gender difference in epileptogenic effects of 2-BFI and BU224 in mice","volume":"718","author":"Min","year":"2013","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.03.009_bb0215","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-3565(25)10130-4","article-title":"Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains","volume":"264","author":"Miralles","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2004.01.017","article-title":"Pharmacological characterisation of acid-induced muscle allodynia in rats","volume":"487","author":"Nielsen","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0225","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.1999.tb09354.x","article-title":"Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes","volume":"881","author":"Olmos","year":"1999","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.03.009_bb0230","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.bjp.0702679","article-title":"Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor","volume":"127","author":"Olmos","year":"1999","journal-title":"British Journal of Pharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0014-2999(96)00519-5","article-title":"Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain","volume":"310","author":"Olmos","year":"1996","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-6147(96)81564-1","article-title":"The elusive family of imidazoline binding sites","volume":"17","author":"Parini","year":"1996","journal-title":"Trends in Pharmacological Sciences"},{"issue":"17\u201318","key":"10.1016\/j.pharmthera.2017.03.009_bb0245","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.drudis.2013.05.017","article-title":"Agmatine: Clinical applications after 100years in translation","volume":"18","author":"Piletz","year":"2013","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0250","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/srep06605","article-title":"Discriminative stimulus effects of the novel imidazoline I(2) receptor ligand CR4056 in rats","volume":"4","author":"Qiu","year":"2014","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FBP.0000000000000028","article-title":"Behavioral effects of the imidazoline I2 receptor ligand BU99006 in rats","volume":"25","author":"Qiu","year":"2014","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2015.01.013","article-title":"Discriminative stimulus effects of the imidazoline I2 receptor ligands BU224 and phenyzoline in rats","volume":"749","author":"Qiu","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0265","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.pa.36.040196.002455","article-title":"Imidazoline receptors and their endogenous ligands","volume":"36","author":"Regunathan","year":"1996","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0165-6147(00)01460-7","article-title":"Is agmatine a novel neurotransmitter in brain?","volume":"21","author":"Reis","year":"2000","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0275","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/mol.58.5.1085","article-title":"Analysis of the pharmacological and molecular heterogeneity of I(2)-imidazoline-binding proteins using monoamine oxidase-deficient mouse models","volume":"58","author":"Remaury","year":"2000","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.03.009_bb0280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WNR.0b013e32834e7db3","article-title":"Effects of imidazoline I2 receptor ligands on acute nociception in rats","volume":"23","author":"Sampson","year":"2012","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0285","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.bjp.0703294","article-title":"Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: A model to detect agonist and antagonist activities at these receptors","volume":"130","author":"Sanchez-Blazquez","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0290","first-page":"161","article-title":"Relationship between the discriminative stimulus properties and subjective effects of drugs","volume":"4","author":"Schuster","year":"1988","journal-title":"Psychopharmacology Series"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.03.009_bb0295","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00213-015-4166-9","article-title":"Interactions between imidazoline I2 receptor ligands and acetaminophen in adult male rats: Antinociception and schedule-controlled responding","volume":"233","author":"Siemian","year":"2016","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.03.009_bb0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.116.232421","article-title":"Antinociceptive interactions between the Imidazoline I2 receptor agonist 2-BFI and opioids in rats: Role of efficacy at the mu-opioid receptor","volume":"357","author":"Siemian","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0305","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.bi.53.070184.003533","article-title":"Polyamines","volume":"53","author":"Tabor","year":"1984","journal-title":"Annual Review of Biochemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2017.03.009_bb0310","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1074\/jbc.270.17.9856","article-title":"Localization of I2-imidazoline binding sites on monoamine oxidases","volume":"270","author":"Tesson","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0021-9258(18)52415-7","article-title":"Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane","volume":"266","author":"Tesson","year":"1991","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.03.009_bb0320","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1476-5381.2012.01894.x","article-title":"Characterization of the hypothermic effects of imidazoline I(2) receptor agonists in rats","volume":"166","author":"Thorn","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.03.009_bb0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/FBP.0000000000000206","article-title":"Antinociceptive effects of imidazoline I2 receptor agonists in the formalin test in rats","volume":"27","author":"Thorn","year":"2016","journal-title":"Behavioural Pharmacology"},{"issue":"18","key":"10.1016\/j.pharmthera.2017.03.009_bb0330","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s00213-015-3983-1","article-title":"Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: Interactions with oxycodone","volume":"232","author":"Thorn","year":"2015","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2017.03.009_bb0335","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/bph.13435","article-title":"Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural\/physical dependence on morphine in rats","volume":"173","author":"Thorn","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0340","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-017-4599-4","article-title":"Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats","author":"Thorn","year":"2017","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2017.03.009_bb0345","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejphar.2011.09.173","article-title":"Effects of imidazoline I(2) receptor ligands on morphine- and tramadol-induced antinociception in rats","volume":"670","author":"Thorn","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.03.009_bb0350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0028-3908(02)00074-6","article-title":"5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: In vitro and in vivo characterisation in rat brain","volume":"43","author":"Tyacke","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.03.009_bb0355","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2014.11.022","article-title":"The influence of microglia activation on the efficacy of amitriptyline, doxepin, milnacipran, venlafaxine and fluoxetine in a rat model of neuropathic pain","volume":"749","author":"Zychowska","year":"2015","journal-title":"European Journal of Pharmacology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581730089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581730089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:08:45Z","timestamp":1750118925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581730089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":71,"alternative-id":["S016372581730089X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.03.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imidazoline I2 receptors: An update","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}